Research and Clinical Trials

Sanofi-Aventis EFC 10262 (Velour): Aflibercept Versus Placebo in Combination With Irinotecan and 5-FU in the Treatment of Patients With Metastatic Colorectal Cancer After Failure of an Oxaliplatin Based Regimen
Brief Description  
The main objective of the study is evaluate the effectiveness of aflibercept in increasing the overall survival in patients with metastatic colorectal cancer treated with irinotecan and 5-FU and that have previously failed an oxaliplatin based treatment for metastatic disease. This project is being conducted at the following locations: Carolinas Medical Center/Blumenthal Cancer Center, Carolinas Hematology-Oncology Associates, and Mecklenburg Medical Group.
Who may be Eligible  
Patients, ages 18 and over, may be eligible if they meet the following criteria:
  • Histologically or cytologically proven adenocarcinoma of the colon or rectum
  • Metastatic disease that is not amenable to potentially curative treatment
  • One and only one prior line of treatment for metastatic disease. This prior line should be an oxaliplatin based chemotherapy (patients who relapse within 6 months of completion of oxaliplatin based adjuvant chemotherapy are eligible)
  • No prior therapy with irinotecan
  • Eastern Cooperative Oncology Group performance status <2
Gastrointestinal Cancer
IRB Number  
Principal Investigator  
Salmon, Stuart

For More Information, Contact  Delois  , DeShazo
Phone:  (704) 355-1342  Fax:  (704) 355-1353  
Email:  Delois.DeShazo
Address:1100 South Tryon Street Suite 220 Charlotte, NC 28203